Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

Andrew Dunn

Senior Biopharma Correspondent

Two former leaders of Recursion Pharmaceuticals have started their own biotech startup, hoping to bring a similar data-obsessed mentality to cancer research.

The San Francisco-based company called Noetik launched Thursday, announcing a $14 million seed round led by DCVC. Its two co-founders are CEO Ron Alfa, formerly head of research at Recursion, and CSO Jacob Rinaldi, who previously led oncology research at the Utah biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

Andrew Dunn

Senior Biopharma Correspondent

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Ex­clu­sive: Two ex-Re­cur­sion lead­ers start Noetik in a bid to fix the bro­ken fun­nel in can­cer drug re­search

Andrew Dunn

Senior Biopharma Correspondent

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients